These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39400108)

  • 21. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    McMurray JJV; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Anand IS; Bělohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett JG; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Petrie MC; Vinh PN; Schou M; Tereshchenko S; Verma S; Held C; DeMets DL; Docherty KF; Jhund PS; Bengtsson O; Sjöstrand M; Langkilde AM;
    N Engl J Med; 2019 Nov; 381(21):1995-2008. PubMed ID: 31535829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
    Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
    Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved.
    Rastogi T; Ferreira JP; Butler J; Kraus BJ; Mattheus M; Brueckmann M; Filippatos G; Wanner C; Pocock SJ; Packer M; Anker SD; Zannad F
    Eur J Heart Fail; 2024 Apr; 26(4):885-896. PubMed ID: 38247160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
    Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
    Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
    Nassif ME; Windsor SL; Borlaug BA; Kitzman DW; Shah SJ; Tang F; Khariton Y; Malik AO; Khumri T; Umpierrez G; Lamba S; Sharma K; Khan SS; Chandra L; Gordon RA; Ryan JJ; Chaudhry SP; Joseph SM; Chow CH; Kanwar MK; Pursley M; Siraj ES; Lewis GD; Clemson BS; Fong M; Kosiborod MN
    Nat Med; 2021 Nov; 27(11):1954-1960. PubMed ID: 34711976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ; Brunton SA; Rangaswami J
    Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
    Anker SD; Butler J; Filippatos G; Shahzeb Khan M; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Seronde MF; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Eur J Heart Fail; 2020 Dec; 22(12):2383-2392. PubMed ID: 33251670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
    Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
    JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
    J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empagliflozin (Jardiance) for heart failure with reduced ejection fraction.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):171-172. PubMed ID: 35085205
    [No Abstract]   [Full Text] [Related]  

  • 37. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
    Banerjee M; Pal R; Nair K; Mukhopadhyay S
    Indian Heart J; 2023; 75(2):122-127. PubMed ID: 36914068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
    McMurray JJV; DeMets DL; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD;
    Eur J Heart Fail; 2019 May; 21(5):665-675. PubMed ID: 30895697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
    Mc Causland FR; Claggett BL; Vaduganathan M; Desai A; Jhund P; Vardeny O; Fang JC; de Boer RA; Docherty KF; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
    JAMA Cardiol; 2024 Feb; 9(2):144-152. PubMed ID: 37952176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
    Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.